Lapatinib Teva (Lapatinib)

Lapatinib blocks the intracellular kinase activity of EGFR (HER1) and HER2 receptors. By preventing ATP binding, it stops downstream signaling through pathways such as MAPK and PI3K/AKT, which are essential for cancer cell proliferation and survival.

The specific dose of Lapatinib Teva is determined by the prescribing physician based on the patient’s clinical condition, treatment regimen, and tolerability. Dosing information is provided in the product label and should be followed exactly as prescribed.

The safety of Lapatinib in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out. Consultation with a healthcare professional is essential.

To request Lapatinib Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lapatinib is a small‑molecule tyrosine kinase inhibitor that targets the intracellular domain of HER2, whereas agents like trastuzumab are monoclonal antibodies that bind the extracellular portion. This difference can affect administration routes, combination options, and resistance profiles, making each suitable for specific clinical scenarios.

Lapatinib Teva tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Lapatinib Teva is taken orally, usually once daily, with a low‑fat meal or as directed by the treating physician. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include hepatotoxicity, cardiac dysfunction such as reduced left‑ventricular ejection fraction, and severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, cardiac function, and any signs of severe dermatologic events.

Lapatinib is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be avoided in individuals with severe hepatic impairment or uncontrolled cardiac disease, and it is not recommended for use during pregnancy or breastfeeding.